Snapshot from May 30, 2026 at 07:00 UTC. For live data and tracking: View Live
Events / Business / Zydus Lifesciences acquires Assertio Holdings
Business acquisition

Zydus Lifesciences acquires Assertio Holdings

Analysis based on 9 articles · First reported May 13, 2026 · Last updated May 14, 2026

Sentiment
60
Attention
4
Articles
9
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The acquisition of Assertio Holdings by Astec LifeSciences is expected to positively impact Astec LifeSciences' stock by strengthening its specialty and oncology presence in the US. Assertio Holdings' shareholders will benefit from the all-cash deal, leading to its delisting from Nasdaq-100.

Pharmaceuticals Biotechnology
Event Summary

Astec LifeSciences, through its subsidiary Cadila Healthcare — Zydus Worldwide DMCC, is set to acquire US-based pharmaceutical company Assertio Holdings for $166.4 million in an all-cash deal. The acquisition, expected to close in the second quarter of calendar 2026 or financial year 2026-27, will be executed via a tender offer followed by a merger. Assertio Holdings' board approved the transaction, deeming Astec LifeSciences' proposal superior to an earlier merger agreement with Garda Therapeutics, which was subsequently terminated. This strategic move will provide Astec LifeSciences with an established specialty oncology commercial platform in the US, anchored by Assertio Holdings' oncology supportive-care portfolio, including its key product Rolvedon. Dr Sharvil Patel, Managing Director of Astec LifeSciences, highlighted that this transaction aligns with the company's long-term strategy of building differentiated specialty businesses globally.

Key Actions
90 Astec LifeSciences acquire Assertio Holdings
80 Assertio Holdings terminate agreement Garda Therapeutics
Entities Involved
stock
Astec LifeSciences
Astec LifeSciences is acquiring Assertio Holdings to strengthen its specialty and oncology footprint in the US, leveraging Assertio's commercial platform and oncology assets.
Importance 100 Sentiment 70
stock
Assertio Holdings
Assertio Holdings is being acquired by Astec LifeSciences for $166.4 million, providing its shareholders with value certainty and execution capability. It will be delisted from Nasdaq-100 upon completion.
Importance 100 Sentiment 80
subs
Cadila Healthcare — Zydus Worldwide DMCC
Cadila Healthcare — Zydus Worldwide DMCC, a subsidiary of Astec LifeSciences, is the direct entity executing the acquisition of Assertio Holdings.
Importance 70 Sentiment 60
per
Sharvil Patel
Sharvil Patel, Managing Director of Astec LifeSciences, views this acquisition as a strategic step to strengthen the company's specialty and oncology footprint in the US.
Importance 70 Sentiment 60
priv
Garda Therapeutics
Assertio Holdings' board terminated an earlier merger agreement with Garda Therapeutics to proceed with the Astec LifeSciences acquisition, deeming Zydus's offer superior.
Importance 30 Sentiment -20
index
Nasdaq-100
Assertio Holdings will be delisted from Nasdaq-100 upon the completion of its acquisition by Astec LifeSciences.
Importance 20 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration approved Rolvedon, a key product in Assertio Holdings' portfolio, for the prevention of febrile neutropenia.
Importance 10 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.